Saratov JOURNAL of Medical and Scientific Research

Transarterial chemoembolization for primary and metastatic liver tumors

Year: 2016, volume 12 Issue: №4 Pages: 716-720
Heading: Oncology Article type: Review
Authors: Popov M.V., Aronov M.S., Voskanyan S.E., Karpova O.V.
Organization: State Scientific Research Center n.a. A.I. Burnasyan — Federal Medical Biophysical Center of Federal Medical Biological Agency

The literature review presents the methodology of transarterial chemoembolization (TACE) — widely used method of treatment of primary and secondary liver tumors. The TACE role as a neoadjuvant therapy and the role in the management of unresectable primary and secondary liver tumors are shown. The morphofunctional basis of TACE, benefits of superselective intra-arterial administration of cytostatic agents especially in combination with ischemic impact on a tumor are described. The subject of the choice of the chemotherapeutic agent is also touched; modern drug-loaded microspheres which allow the use of higher doses of the chemotherapeutic drug without increasing systemic effect and prolong its effect on tumor are described. Lack of correlation of presence and severity of a post-embolization syndrome with success of the procedure is noted.

1. Venook АР, Papandreou С, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 (4): 5-13
2. Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. Surg Clin North Am 2013; (9): 1423-1450
3. Craig JR, Peters RL, Edmondson HA. Tumors of the Liver and Intrahepatic Bile Ducts. Atlas of Tumor Pathology, 2nd series, 26. Washington, DC: Armed Forces Institute of Pathology, 1989
4. Pickren JW, Tsukada Y, Lane WW. Liver metastases: analysis of autopsy data. In: Weiss L, Gilbert HA, eds. Liver Metastasis. Boston, MA: Hall Medical Publishers, 1982; p. 2-18
5. Hong SN, Lee SY, Choi MS, et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005; 39: 247-52
6. Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004; 240: 102-7
7. Allemann P, Demartines N, Bouzourene H, et al. Long-term outcome after liver resection for hepatocellular carcinoma larger than 10cm. World J Surg 2013; 37 (2): 452-458
8. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007; 11:1057-77
9. Eynde M van den, Hendlisz A. Treatment of colorectal liver metastases: a review. Rev Recent Clin Trials 2009; 4: 56-62
10. Lencioni R, Chen XP, Dagher L, Venook AP Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: How can outcomes be improved? Oncologist 2010; 15 (Suppl 4): 42-52
11. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surgery 2004; 240 (4): 644-58
12. Namasivayam S, Salman K, Mittal PK, et al. Hypervascular hepatic focal lesions: spectrum of imaging features. Curr Probl Diagn Radiol 2007; 36: 107-23
13. Sahani DV, Kalva SP Imaging the liver. Oncologist 2004; 9: 385-97
14. Brink JA. Use of high concentration contrast media (HCCM): principles and rationale — body CT. Eur J Radiol 2003; 45 (Suppl 1):53-8
15. Granov DA, Tarazov PG. Roentgenoendovascular interventions in the treatment of malignant liver tumors. St. Petersburg: Foliant, 2002
16. Granov AM, Davydov Ml. Interventional radiology in oncology (ways of development and technology). St. Petersburg: Foliant, 2007
17. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. The Oncologist 2003; 8: 553-66
18. Ramsey DE, Kernagis LY, Soulen MC, et al. Chemoembolization of hepatocellular carcinoma. J Vase Interv Radiol 2002; 13:211-21
19. Kruskal JB, Hlatky L, Hahnfeldt P, et al. In-vivo and in-vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vase Interv Radiol 1993;4:741-8
20. Huang K, Zhou Q, Wang R, et al. Doxorubicineluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 920-925
21. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25
22. Ono Y, Yoshimasu T, Ashikaga R, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 2000; 23: 564-8
23. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71
24. Llovet JM, Real Ml, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 1734-9
25. Yao FY, Kerlan RK, Hirose R, et al. Excellent outcomes following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48(3): 819-827
26. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4: 424-432
27. Lesurtel M, Mullhaupt B, Pestalozzi ВС, et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6(11): 2644-50
28. Maddala YK, Stadheim L, Andrews JC, et al. Dropout rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004; 10:449-55
29. Richard HM 3rd, Silberzweig JE, Mitty HA, et al. Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellulat carcinoma. Radiology 2000; 214: 775-9
30. Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007; 17: 1025-34
31. Martinelli DJ, Wadler S, Bakal CW, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994; 74: 1706-12
32. Lang EK, Brown CL. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993; 189: 417-22
33. Taniai N, Onda M, Tajiri T, et al. Good embolization response for colorectal liver metastases with hypervascularity Hepatogastroenterology 2002; 49: 1531-4
34. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241: 776-83
35. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511
36. Ruszniewski P, OToole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 2004; 80 (Suppl 1): 74-8
37. Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma:natural history, current management, and emerging tools. Biologies 2012; 6: 207-219
38. Chan АО, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2001; 94: 1747-52
39. Wigmore SJ, Redhead DN, Thomson BN, et al. Postchemoembolization syndrome: tumour necrosis or hepatocyte injury? Br J Cancer 2003; 89: 1423-7.

2016_04-1_716-720.pdf254.88 KB

No votes yet